计算溶液所需的质量、体积或浓度。
Elotuzumab (anti-SLAMF7) (Ab169272) - ELISA
Immobilized huSLAMF7-Fc at 2 μg/mL can bind Elotuzumab (anti-SLAMF7) (Ab169272) with the EC₅₀ of 18.15 ng/mL.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab169272-100μg |
100μg |
现货 ![]() |
| |
| Ab169272-1mg |
1mg |
现货 ![]() |
| |
| Ab169272-5mg |
5mg |
现货 ![]() |
| |
| Ab169272-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Elotuzumab (anti-SLAMF7), CS1 (CD319) 抗体 |
|---|---|
| 别名 | 埃罗妥珠单抗 | 埃罗妥珠单抗(抗 SLAMF7) |
| 英文别名 | Recombinant Elotuzumab Antibody | Elotuzumab | HuLuc 63 | PDL 063 | BMS 901608 | Elotuzumab (anti-SLAMF7) | BMS-901608 | PDL063 | HuLuc63 | Empliciti | 19A antibody | 19A24 protein antibody | CD 319 antibody | CD2 like receptor activating cytotoxic cells |
| 规格或纯度 | 无载体, 重组, ExactAb™, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | SLAMF7 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | CS1 (CD319) 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.1 kDa (Light Chain) & 52.3 kDa (Heavy Chain), under reducing conditions; 173.0 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 915296-00-3 |
| 分子类型 | 抗体 |
Elotuzumab (anti-SLAMF7) (Ab169272) - ELISA
Immobilized huSLAMF7-Fc at 2 μg/mL can bind Elotuzumab (anti-SLAMF7) (Ab169272) with the EC₅₀ of 18.15 ng/mL.
Elotuzumab (anti-SLAMF7) (Ab169272) - SEC
The purity of Elotuzumab (anti-SLAMF7) (Ab169272) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-03-08 | Ab169272 | |
| 分析证书 | 24-03-08 | Ab169272 | |
| 分析证书 | 24-03-08 | Ab169272 |
¥669.90
¥669.90
| 1. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG et al.. (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.. Blood, 112 (4): (1329-37). [PMID:17906076] |
| 2. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y et al.. (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.. Clin Cancer Res, 14 (9): (2775-84). [PMID:18451245] |
| 3. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R et al.. (2009) Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.. Mol Cancer Ther, 8 (9): (2616-24). [PMID:19723891] |
| 4. Veillette A, Guo H. (2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.. Crit Rev Oncol Hematol, 88 (1): (168-77). [PMID:23731618] |